Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LISA B CONNERY

Allopathic & Osteopathic Physicians Family Medicine

NPI
1205828977
CMS profile
9503
Location
NORMAN, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$18,360.32

113 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $14,200.59 40
Consulting Fee $2,100.00 1
Food and Beverage $1,934.19 69
Education $125.54 3

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LISA B CONNERY

NPI 1205828977 · CMS profile ID 9503

Allopathic & Osteopathic Physicians / Family Medicine

NORMAN, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205828977?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LISA B CONNERY, NPI 1205828977, CMS profile ID 9503. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205828977?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LISA B CONNERY, NPI 1205828977, CMS profile ID 9503. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205828977?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LISA B CONNERY, NPI 1205828977, CMS profile ID 9503, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–113 of 113 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1205828977?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

113 matching records · $18,360.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 113 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–113 of 113.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eli Lilly and Company $18.0803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031880877 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031880881 CMS
Eli Lilly and Company $3.9803/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031880885 CMS
Eli Lilly and Company $139.3603/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031880891 CMS
Eli Lilly and Company $475.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031880897 CMS
Eli Lilly and Company $24.9903/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031906243 CMS
Eli Lilly and Company $13.9303/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031906247 CMS
Eli Lilly and Company $199.0003/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031906251 CMS
AbbVie Inc. $19.8301/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996503011 CMS
AstraZeneca Pharmaceuticals LP $14.8201/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015002301 CMS
IDORSIA PHARMACEUTICALS US INC $17.0301/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034299237 CMS
Lilly USA, LLC $9.2301/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031856385 CMS
Exact Sciences Corporation $15.5101/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026646443 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $15,946.77 131
PY2020 $2,326.98 56
PY2021 $10,760.98 15
PY2022 $2,362.95 25
PY2023 $18,360.32 113
PY2024 $12,874.79 95
PY2025 $42,664.99 132

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,947,402.59 237
PY2024 Recipient $38,645.81 22
PY2024 Principal investigator $3,031,009.48 70
PY2023 Recipient $649.72 3
PY2023 Principal investigator $2,692,454.09 131
PY2022 Recipient $26,997.21 15
PY2022 Principal investigator $1,957,706.53 125
PY2021 Principal investigator $2,228,001.31 608
PY2020 Recipient $12,692.04 9
PY2020 Principal investigator $1,474,593.52 211
PY2019 Recipient $22,840.16 19
PY2019 Principal investigator $1,166,870.19 166

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

237 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,795.80 12/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278924
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $210.00 12/15/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798475
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $29,877.26 12/15/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798477
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,797.50 12/15/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798479
Principal investigator 1 PFIZER INC. $1,287.00 12/15/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728545
Principal investigator 1 PFIZER INC. $1,287.00 12/15/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228729156
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,200.00 12/10/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798473
Principal investigator 1 Hoffmann-La Roche Limited $5,959.00 12/04/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211663884
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,988.00 12/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185552271
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658560
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658562
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 12/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658564
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658566
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658568
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658570
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658572
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658574
Principal investigator 1 Genentech, Inc. $1,800.00 11/26/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211663808
Principal investigator 1 PFIZER INC. $704.90 11/26/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228727967
Principal investigator 1 Hoffmann-La Roche Limited $19,247.00 11/20/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211663862
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 11/19/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658580
Principal investigator 1 Boehringer Ingelheim International GmbH $24.36 11/19/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658582
Principal investigator 1 Hoffmann-La Roche Limited $9,213.00 11/14/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211663871
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,655.20 11/14/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $688.80 11/14/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 11/14/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $83.00 11/14/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261299
Principal investigator 1 Hoffmann-La Roche Limited $108.00 11/07/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211663856
Principal investigator 1 Hoffmann-La Roche Limited $8,499.00 11/07/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211663865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,349.40 11/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258875
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,349.40 11/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258877
Principal investigator 1 PFIZER INC. $12,250.00 11/04/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228707523
Principal investigator 1 PFIZER INC. $9,607.15 11/04/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228738180
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658548
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658550
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658552
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658554
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658556
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658558
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,376.88 10/29/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798471
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/27/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658576
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 10/27/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,103.00 10/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,369.80 10/16/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250471
Principal investigator 1 Eli Lilly and Company $3,486.99 10/14/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF LY3549492 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS 55 TO 80 YEARS OF AGE AND BMI WITHIN 22 TO 25 KG/M2 No dispute reported 06/30/2026 1187874509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,820.80 10/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244499
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,717.80 10/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244515
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658536
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658538
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658540
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658542
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658544
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658546
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 09/24/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658534
Principal investigator 1 PFIZER INC. $20,984.53 09/24/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228752975
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $420.00 09/23/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798467
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,595.00 09/23/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798469
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 09/19/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220795149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,922.40 09/18/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56,467.60 09/10/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235841
Principal investigator 1 PFIZER INC. $6,660.15 09/09/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228753524
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $29,335.32 09/03/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798465
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,900.00 09/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,920.10 09/03/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184234989
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658500
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658502
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658504
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658506
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658508
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658526
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $210.00 08/28/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798459
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $315.00 08/28/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798461
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $525.00 08/28/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798463
Principal investigator 1 Hoffmann-La Roche Limited $16,330.00 08/26/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211663820
Principal investigator 1 PFIZER INC. $12,714.45 08/26/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228719771
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,675.80 08/26/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,675.80 08/26/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $587.30 08/26/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,813.00 08/26/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230683
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $151.20 08/26/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184230685
Principal investigator 1 AstraZeneca UK Limited $9,915.60 08/13/2025 Non-covered Recipient Entity
ALABAMA KIDNEY RESEARCH
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185552269
Principal investigator 1 PFIZER INC. $271.80 08/08/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228707343
Principal investigator 1 PFIZER INC. $131.75 08/08/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228707525
Principal investigator 1 PFIZER INC. $757.50 08/08/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228707598
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40,629.82 08/06/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798457
Principal investigator 1 PFIZER INC. $24,607.10 08/05/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228768367
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658488
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658490
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658492
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658494
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658496
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658498
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658520
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658524
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $210.00 07/30/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798455
Principal investigator 1 Amgen Inc. $25,092.23 07/28/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246639007
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 07/28/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658528
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 07/28/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658530
Principal investigator 1 Boehringer Ingelheim International GmbH $13.92 07/28/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658532
Principal investigator 1 PFIZER INC. $3,412.80 07/22/2025 Non-covered Recipient Entity
AMR Clinical
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228707345
Principal investigator 1 PFIZER INC. $550.00 07/18/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228762669
Principal investigator 1 AstraZeneca UK Limited $73,150.00 07/16/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight or Obesity No dispute reported 06/30/2026 1185552273
Principal investigator 1 PFIZER INC. $34,780.52 07/15/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228788384
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $174.00 07/09/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798451
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $630.00 07/09/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,174.60 07/04/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212723
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658510
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658512
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658514
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658516
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658518
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658522
Principal investigator 1 PFIZER INC. $42,339.99 06/26/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228775857
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $42,959.28 06/25/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798449
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 06/24/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658482
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 06/24/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658484
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 06/24/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658486
Principal investigator 1 Amgen Inc. $27,626.20 06/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246639061
Principal investigator 1 Eli Lilly and Company $411.00 06/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 1187872559
Principal investigator 1 Eli Lilly and Company $419.00 06/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) No dispute reported 06/30/2026 1187874499
Principal investigator 1 Eli Lilly and Company $645.00 06/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A STUDY OF TIRZEPATIDE (LY3298176) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES SWITCHING FROM DULAGLUTIDE (SURPASS-SWITCH) (SURPASS-SWITCH) No dispute reported 06/30/2026 1187874501
Principal investigator 1 Eli Lilly and Company $14,309.00 06/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3B, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED TO SEMAGLUTIDE 2.4 MG IN ADULTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (SURMOUNT-5) No dispute reported 06/30/2026 1187875835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,400.00 06/12/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206191
Principal investigator 1 F. Hoffmann-La Roche AG $5,210.00 06/11/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211663758
Principal investigator 1 Eli Lilly and Company $133,442.00 06/10/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) No dispute reported 06/30/2026 1187875197
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,400.00 06/05/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204127
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658462
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658464
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658466
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658468
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658470
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658472
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 05/27/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658480
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,410.00 05/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798445
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,944.40 05/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798447
Principal investigator 1 Eli Lilly and Company $33,896.00 05/27/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL No dispute reported 06/30/2026 1187875205
Principal investigator 1 Eli Lilly and Company $369.50 05/27/2025 Non-covered Recipient Entity
INTEND RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187881632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/22/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,883.00 05/22/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197549
Principal investigator 1 PFIZER INC. $34,803.44 05/14/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228771546
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $19,740.14 05/09/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798443
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,883.00 05/08/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193723
Principal investigator 1 PFIZER INC. $10,327.52 05/06/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228774201
Principal investigator 1 Eli Lilly and Company $6,837.00 05/05/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187876295
Principal investigator 1 PFIZER INC. $23,413.39 05/03/2025 Non-covered Recipient Entity
Alliance for Multispecialty Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228762788
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658442
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658444
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658446
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658448
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658450
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658452
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658454
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658456
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658458
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658460
Principal investigator 1 Eli Lilly and Company $240.00 04/30/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) No dispute reported 06/30/2026 1187872561
Principal investigator 1 Eli Lilly and Company $165.00 04/30/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187874503
Principal investigator 1 Eli Lilly and Company $165.00 04/30/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187875841
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,336.80 04/28/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190791
Principal investigator 1 Amgen Inc. $4,729.00 04/24/2025 Non-covered Recipient Entity
INTEND RESEARCH, LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246642830
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 04/23/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658474
Principal investigator 1 Boehringer Ingelheim International GmbH $2,299.50 04/23/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658476
Principal investigator 1 Boehringer Ingelheim International GmbH $74.82 04/23/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $295.40 04/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189119
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $159.60 04/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189129
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,206.80 04/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $71.40 04/23/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189135
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $4,652.82 04/17/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PARALLEL-GROUP TREATMENT, PHASE 2, DOUBLE-BLIND STUDY OF ONCE-WEEKLY SUBCUTANEOUS LY3457263 COMPARED TO PLACEBO IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS ON A STABLE DOSE OF TIRZEPATIDE OR SEMAGLUTIDE WHO FAILED TO ACHIEVE HBA1C GOAL No dispute reported 06/30/2026 1187875211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,314.40 04/15/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183440
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $46,886.14 04/11/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798441
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658430
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658432
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658434
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658436
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658438
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658440
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,552.80 03/19/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174602
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23,924.74 03/18/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798439
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658390
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658392
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658394
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658396
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658398
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 03/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658400
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 03/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658402
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658404
Principal investigator 1 Boehringer Ingelheim International GmbH $399.60 02/25/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658416
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 02/25/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658418
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 02/25/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658420
Principal investigator 1 Boehringer Ingelheim International GmbH $55.20 02/25/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658422
Principal investigator 1 Eli Lilly and Company $16,028.38 02/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187875199
Principal investigator 1 Eli Lilly and Company $256.52 02/25/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187876291
Principal investigator 1 Eli Lilly and Company $1,308.65 02/25/2025 Non-covered Recipient Entity
INTEND RESEARCH LLC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187882084
Principal investigator 1 F. Hoffmann-La Roche AG $15,500.00 02/25/2025 Non-covered Recipient Entity
THE ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
CT-388-104 OW/OB with T2D No dispute reported 06/30/2026 1211663754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,406.80 02/18/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154170
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658378
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658380
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658382
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658384
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658386
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658388
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187872555
Principal investigator 1 Eli Lilly and Company $260.00 01/31/2025 Non-covered Recipient Entity
INTEND RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187882172
Principal investigator 1 Eli Lilly and Company $887.97 01/31/2025 Non-covered Recipient Entity
INTEND RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187882882
Principal investigator 1 Eli Lilly and Company $405.00 01/31/2025 Non-covered Recipient Entity
INTEND RESEARCH LLC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187883564
Principal investigator 1 Eli Lilly and Company $405.00 01/31/2025 Non-covered Recipient Entity
INTEND RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187883864
Principal investigator 1 Amgen Inc. $6,284.00 01/30/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246639017
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,068.40 01/29/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149844
Principal investigator 1 Amgen Inc. $413,453.96 01/27/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246639047
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 01/27/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658406
Principal investigator 1 Boehringer Ingelheim International GmbH $693.50 01/27/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658408
Principal investigator 1 Boehringer Ingelheim International GmbH $1.24 01/27/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658410
Principal investigator 1 Boehringer Ingelheim International GmbH $1.16 01/27/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658412
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 01/27/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658414
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $45,060.40 01/27/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798437
Principal investigator 1 Eli Lilly and Company $328.67 01/27/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187876531
Principal investigator 1 Amgen Inc. $69,000.06 01/22/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH
A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM No dispute reported 06/30/2026 1246639071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,012.00 01/21/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149042
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,580.98 01/17/2025 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220798435
Principal investigator 1 Eli Lilly and Company $46,897.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187871547
Principal investigator 1 Eli Lilly and Company $41,085.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187874487
Principal investigator 1 Eli Lilly and Company $80,870.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187875193
Principal investigator 1 Eli Lilly and Company $390,126.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A STUDY OF ORFORGLIPRON FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES (ATTAIN-MAINTAIN) No dispute reported 06/30/2026 1187875195
Principal investigator 1 Eli Lilly and Company $144,026.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) No dispute reported 06/30/2026 1187875959
Principal investigator 1 Eli Lilly and Company $28,682.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187876281
Principal investigator 1 Eli Lilly and Company $158,087.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187876283
Principal investigator 1 Eli Lilly and Company $296,994.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A STUDY OF LY3298176 (TIRZEPATIDE) FOR THE MAINTENANCE OF BODY WEIGHT REDUCTION IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES No dispute reported 06/30/2026 1187876307
Principal investigator 1 Eli Lilly and Company $20,825.00 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLS
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL ORFORGLIPRON COMPARED WITH DAPAGLIFLOZIN IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-2) No dispute reported 06/30/2026 1187876309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,490.60 01/07/2025 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145774
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658368
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658370
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658372
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658374
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658376
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 01/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658424
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658426
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 01/01/2025 Non-covered Recipient Entity
Amr Norman
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220658428